Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other financing activities (2016 - 2023)

Viking Therapeutics (VKTX) has disclosed Other financing activities for 8 consecutive years, with $37000.0 as the latest value for Q1 2023.

  • For Q1 2023, Other financing activities changed N/A year-over-year to $37000.0; the TTM value through Mar 2023 reached $56000.0, changed N/A, while the annual FY2022 figure was $22000.0, 52.17% down from the prior year.
  • Other financing activities hit $37000.0 in Q1 2023 for Viking Therapeutics, up from $19000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $37000.0 in Q1 2023 and bottomed at $7000.0 in Q4 2019.
  • Average Other financing activities over 3 years is $21000.0, with a median of $19000.0 recorded in 2021.
  • On a YoY basis, Other financing activities climbed as much as 97.53% in 2019 and fell as far as 97.53% in 2019.
  • Viking Therapeutics' Other financing activities stood at $7000.0 in 2019, then skyrocketed by 171.43% to $19000.0 in 2021, then surged by 94.74% to $37000.0 in 2023.
  • According to Business Quant data, Other financing activities over the past three periods came in at $37000.0, $19000.0, and $7000.0 for Q1 2023, Q4 2021, and Q4 2019 respectively.